Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
Akero Therapeutics (Nasdaq: AKRO), a clinical-stage biotechnology company focused on developing treatments for serious metabolic diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management will deliver a presentation on Wednesday, June 4, 2025, at 8:45 a.m. Pacific Time. Investors and interested parties can access the live webcast through Akero's investor relations website section at www.akerotx.com, with an archived replay available after the event.
Akero Therapeutics (Nasdaq: AKRO), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di trattamenti per gravi malattie metaboliche, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. Il management dell'azienda terrà una presentazione mercoledì 4 giugno 2025 alle 8:45, ora del Pacifico. Investitori e interessati potranno seguire la diretta streaming attraverso la sezione relazioni con gli investitori del sito www.akerotx.com, con la possibilità di rivedere la registrazione dopo l'evento.
Akero Therapeutics (Nasdaq: AKRO), una empresa biotecnológica en fase clínica centrada en el desarrollo de tratamientos para enfermedades metabólicas graves, ha anunciado su participación en la próxima Jefferies Global Healthcare Conference. La dirección de la empresa realizará una presentación el miércoles 4 de junio de 2025 a las 8:45 a.m. hora del Pacífico. Inversores y partes interesadas podrán acceder a la transmisión en vivo a través de la sección de relaciones con inversores en www.akerotx.com, con una repetición archivada disponible después del evento.
Akero Therapeutics(나스닥: AKRO)는 심각한 대사 질환 치료제 개발에 주력하는 임상 단계의 생명공학 회사로, 다가오는 Jefferies Global Healthcare Conference에 참가한다고 발표했습니다. 회사 경영진은 2025년 6월 4일 수요일 태평양 시간 오전 8시 45분에 발표를 진행할 예정입니다. 투자자 및 관심 있는 분들은 Akero 투자자 관계 웹사이트(www.akerotx.com)를 통해 생중계에 접속할 수 있으며, 행사 후에는 녹화 다시보기도 제공됩니다.
Akero Therapeutics (Nasdaq : AKRO), une société biotechnologique en phase clinique spécialisée dans le développement de traitements pour des maladies métaboliques graves, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. La direction de l'entreprise présentera le mercredi 4 juin 2025 à 8h45, heure du Pacifique. Les investisseurs et les personnes intéressées pourront accéder à la diffusion en direct via la section relations investisseurs du site www.akerotx.com, avec une rediffusion disponible après l'événement.
Akero Therapeutics (Nasdaq: AKRO), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für schwere Stoffwechselerkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference angekündigt. Die Geschäftsführung des Unternehmens wird am Mittwoch, den 4. Juni 2025, um 8:45 Uhr Pazifischer Zeit eine Präsentation halten. Investoren und Interessierte können den Live-Webcast über den Bereich Investor Relations auf der Website www.akerotx.com verfolgen; eine Aufzeichnung wird nach der Veranstaltung verfügbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 8:45 a.m. P.T.
A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero’s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, and SYNCHRONY Real-World in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.
Investor Contact:
Christina Tartaglia
Precision AQ
332.322.7430
Christina.tartaglia@precisionaq.com
Media Contact:
Peg Rusconi
617.910.6217
peg.rusconi@deerfieldgroup.com
FAQ
When is Akero Therapeutics (AKRO) presenting at the Jefferies Global Healthcare Conference 2025?
How can I watch Akero Therapeutics' (AKRO) presentation at the Jefferies Conference?
What type of company is Akero Therapeutics (AKRO)?
Where can I find the replay of AKRO's Jefferies Conference presentation?
